Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus ...

Crohn's disease or ulcerative colitis. Though the two have similar symptoms, they require different ... July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ...

Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

A NEW method for detecting bowel cancer is more than 90 per cent accurate at predicting which higher risk people will develop ...

A new test developed in the UK can accurately predict whether high-risk patients will develop bowel cancer, also known as ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of ...

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...